Immune checkpoint blockade (ICB) therapy has achieved breakthroughs in the treatment of
advanced non–small cell lung cancer (NSCLC). Nevertheless, the low response due to …

BACKGROUND. Immune checkpoint blockade improves survival in a subset of patients with
non–small-cell lung cancer (NSCLC), but robust biomarkers that predict response to PD-1 …

Introduction Epithelial-to-mesenchymal transition (EMT) is associated with tumor
aggressiveness, drug resistance, and poor survival in non-small cell lung cancer (NSCLC) …

Non–small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths. Immune
checkpoint blockade has improved survival for many patients with NSCLC, but most fail to …

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …

Tuberous sclerosis complex subunit 1 (TSC1) and 2 (TSC2) are frequently mutated in non–
small cell lung cancer (NSCLC), however, their effects on antitumor immunity remained …

Immune checkpoint inhibitor (ICI) treatment has recently become a first-line therapy for many
non–small cell lung cancer (NSCLC) patients. Unfortunately, most NSCLC patients are …

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-
1/programmed cell death ligand-1 axis have significantly shifted the treatment paradigm in …

Background Immunotherapy has revolutionized clinical outcomes for patients suffering from
lung cancer, yet relatively few patients sustain long-term durable responses. Recent studies …

Characterizing the molecular immune subtype and micro-environment of lung cancer is
necessary to understand immunogenic interactions between infiltrating immune and stromal …